Lee, J. C. (2021) “Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan”, Asian Pacific Journal of Cancer Biology, 6(2), pp. 123–132. doi: 10.31557/apjcb.2021.6.2.123-132.